Irradiated p53-wild-type medulloblastoma cells enter senescence and remain vulnerable to senolytics

Gamma irradiation induced p53/p21-dependent senescence in ONS76 medulloblastoma cells, which could subsequently be eliminated by several senolytic agents in vitro.

KEY POINTS

  • The investigators compared two SHH-activated pediatric medulloblastoma cell lines with different p53 status: ONS76 with wild-type p53 and UW228-3 with mutated p53. Cells were exposed to gamma irradiation across several doses, including 4, 9, 16, and 20 Gy.
  • Despite similar conventional SF2-based radioresistance measures, the biological response to irradiation differed fundamentally. Following 20 Gy, UW228-3 cells detached and died within approximately 3–7 days, whereas ONS76 cells remained viable with a flattened, enlarged senescent morphology that persisted for more than 50 days.
  • In ONS76 cells, irradiation produced multiple hallmarks of cellular senescence: increasing senescence-associated β-galactosidase activity, lipofuscin accumulation, stabilization of p53, and induction of the CDK inhibitor p21. Irradiated UW228-3 cells instead showed increased LDH release and caspase activity consistent with apoptosis.
  • The senescent phenotype was mechanistically dependent on the p53/p21 pathway. siRNA knockdown of either p53 or p21 before 16 Gy irradiation substantially increased cell death and reduced the proportion of senescent ONS76 cells.
  • c-Myc expression altered post-radiation cell fate. Forced c-Myc overexpression reduced p21 protein expression and decreased radiation-induced senescence in ONS76, shifting part of the response toward cell death; the effect occurred without a corresponding reduction in p21 mRNA.
  • Seven days after 20 Gy, senescent ONS76 cells were exposed to the senolytics PX-866, copanlisib/BAY80-6946, navitoclax, and venetoclax at 3, 10, and 30 μM. All four agents produced dose-dependent killing of irradiated senescent cells, although navitoclax at the highest concentration also damaged proliferating cells.
  • c-Myc-overexpressing ONS76 cells formed fewer senescent cells after irradiation and were substantially less responsive to subsequent senolytic treatment. The entire study was performed in cell lines, and the high experimental doses used to generate homogeneous senescence should not be interpreted as a proposed clinical radiation schedule.

CLINICAL TAKEAWAY

These experiments suggest that radiation does not always eliminate medulloblastoma cells outright: in p53-wild-type, low-c-Myc cells it can instead create a persistent senescent population that remains pharmacologically targetable. The concept of RT followed by senolytic therapy is biologically interesting, but it is currently preclinical and requires validation in animal models before any conclusions about reducing CSI dose or improving clinical outcomes are justified.

SOURCE

Cell Death Discovery

Browse more research Suggest a correction